pp-132 Tablets
Dossier type
CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Amyotrophic lateral sclerosis (ALS)
Clinical stage: Phase 2
Modality: Small molecule
Mechanism / Target: Selective glucocorticoid receptor (GR) modulator — reduces cortisol-driven neuroinflammation in motor neuron disease; blocks GR-mediated transcription of pro-inflammatory genes
Route / form: Oral tablet
Differentiation: Novel GR modulation approach in ALS (unproven target); oral, once-daily administration; no CNS penetration concerns with selective GR modulator
Manufacturer #4727
Commercial-stage company specialising in glucocorticoid receptor modulation for oncology and endocrine disorders. Holds first-mover advantage with approved GR antagonist and next-generation wholly owned pipeline. Independent US-focused development and commercialisation strategy.